Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619001406190
Ethics application status
Approved
Date submitted
28/09/2019
Date registered
14/10/2019
Date last updated
24/04/2020
Date data sharing statement initially provided
14/10/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Different Diets in Gestational Diabetes
Scientific title
Investigating outcomes of reduced carbohydrate diets in Gestational Diabetes
Secondary ID [1] 299406 0
no secondary ID
Universal Trial Number (UTN)
U1111-1241-0014
Trial acronym
no trial acronym
Linked study record
No linked study

Health condition
Health condition(s) or problem(s) studied:
Gestational Diabetes 314581 0
Condition category
Condition code
Reproductive Health and Childbirth 312923 312923 0 0
Antenatal care
Metabolic and Endocrine 313059 313059 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Individual, face to face dietary information session, advising the participant to aim for a daily carbohydrate intake of 120g. The advice provided is by a qualified dietician at the 'Diabetes in Pregnancy Clinic'. Dietician session usually lasts about 30 -60 minutes.
Intervention code [1] 315656 0
Lifestyle
Comparator / control treatment
Individual, face to face dietary information session, advising the participant to aim for a daily carbohydrate intake of 215g. Advice provided by a qualified dietician at the 'Diabetes in Pregnancy Clinic'. Dietician session usually lasts about 30 -60 minutes.
Control group
Active

Outcomes
Primary outcome [1] 321522 0
Weight gain per week as measured at the 'Diabetes in Pregnancy' clinic visits and recorded in the participant's hospital notes.
Timepoint [1] 321522 0
The initial primary outcome timepoint is when the participant first attends the 'Diabetes in Pregnancy' clinic.

Weight is measured at Diabetes in Pregnancy clinics held every Wednesday, women attend at regular intervals, increasing in frequency to once a week towards the end of their pregnancy.

The final primary outcome timepoint is the last 'Diabetes in Pregnancy 'clinic attended prior to the birth of her baby.
Secondary outcome [1] 375218 0
Average carbohydrate intake per day as measured by a food diary/ 24 hour food recall collected weekly throughout the pregnancy.
Timepoint [1] 375218 0
Food diary/recall collected each week from randomisation till the birth of the baby.
Secondary outcome [2] 375291 0
The proportion of time spent outside the target blood glucose levels on Continuous Glucose Monitoring (CGM). Target range is 4.0 mmol/L to 6.7 mmol /L CGM will occur for 14 days
Timepoint [2] 375291 0
CGM for 14 days commenced at the second visit to the Diabetes in Pregnancy Clinic. This visit is when randomisation to the intervention occurs.
CGM for 14 days measured again starting at 36 weeks gestation.

Eligibility
Key inclusion criteria
Women may be included if they have been diagnosed with gestational diabetes mellitus and present to the Wellington or Keneperu 'Diabetes in Pregnancy' clinics
Minimum age
18 Years
Maximum age
60 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
• First presentation to clinic >31 weeks gestation (Note must be randomised by 32 weeks)
• Type 1 diabetes mellitus
• Known pre-existing type 2 diabetes mellitus
• HbA1c at initial booking greater than or equal to 50mmol/mol
• Needs an interpreter into English for phone call with the research team

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment achieved by computer randomisation package.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
This is a feasability study. We plan to include 20 women who present to the DIP clinic with GDM. This gives about 19 degrees of freedom with which to estimate a 95% CI for the standard deviation of the weight gain per week which gives good precision for this estimation. A lower confidence limit of SD of above 1.0 means that the planned RCT (requiring about 500 participant) could be done in a single centre; and of 1.25 would require two centres. We think the SD of this outcome will be different in the setting of an RCT because in the audit women presented to the clinic at any time between 5 and 39 weeks gestation with variable number of weight measurements. We will recruit women who are at most 32 weeks pregnant so that we will obtain at least six weeks of the intervention and at least two weight measurements whilst on the intervention. In this way the intervention will be as standardised as possible within a clinic environment and with a lesser degree of variability. The analysis of this primary outcome variable will use a Chi-square statistic to estimate the 95% CI for the standard deviation of this variable. Other data analyses, particularly for proportions, will be done however with the modest sample size confidence intervals for proportions will be very wide. The estimation of the difference in reported CHO intake will be by a t-test. Should the lower confidence limit for the estimate of difference in CHO level be less than 50g this will require substantial modification of our intervention to achieve a reasonable separation in CHO intake.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
30/10/2019
Actual
30/10/2019
Date of last participant enrolment
Anticipated
5/02/2020
Actual
14/02/2020
Date of last data collection
Anticipated
16/06/2020
Actual
Sample size
Target
20
Accrual to date
Final
15
Recruitment outside Australia
Country [1] 21886 0
New Zealand
State/province [1] 21886 0
Wellington

Funding & Sponsors
Funding source category [1] 303912 0
University
Name [1] 303912 0
University of Otago
Country [1] 303912 0
New Zealand
Primary sponsor type
Individual
Name
Rosemary Hall
Address
Rosemary Hall,
Endocrinologist.
University of Otago, Wellington
23 Mein St,
Newtown,
Wellington
6242
New Zealand
Country
New Zealand
Secondary sponsor category [1] 304095 0
None
Name [1] 304095 0
Address [1] 304095 0
Country [1] 304095 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304416 0
Northern B Health and Disability Ethics Committee
Ethics committee address [1] 304416 0
Ethics committee country [1] 304416 0
New Zealand
Date submitted for ethics approval [1] 304416 0
15/11/2018
Approval date [1] 304416 0
16/05/2019
Ethics approval number [1] 304416 0
18/NTB/236

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 96878 0
Dr Rosemary Hall
Address 96878 0
University of Otago, Wellington
23 Mein St
Newtown,
Wellington
6242
Country 96878 0
New Zealand
Phone 96878 0
+64 21863370
Fax 96878 0
Email 96878 0
[email protected]
Contact person for public queries
Name 96879 0
Rosemary Hall
Address 96879 0
University of Otago, Wellington
23 Mein St
Newtown,
Wellington
6242
Country 96879 0
New Zealand
Phone 96879 0
+64 21863370
Fax 96879 0
Email 96879 0
[email protected]
Contact person for scientific queries
Name 96880 0
Rosemary Hall
Address 96880 0
University of Otago, Wellington
23 Mein St
Newtown,
Wellington
6242
Country 96880 0
New Zealand
Phone 96880 0
+64 21863370
Fax 96880 0
Email 96880 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Because this is a feasibility study to assess effectiveness for a future RCT. We expect this will be of great importance to our team for future planning, but not of great significance to other researchers.


What supporting documents are/will be available?




Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.